Weight loss drug could enhance outcomes in Type 2 diabetes
Semaglutide could be effective at reducing the risk of stroke in patients with Type 2 diabetes.
In a study published in the Annals of Internal Medicine, investigators used electronic health records to examine the outcomes of more than 15,000 adult patients with Type 2 diabetes who received either semaglutide or empagliflozin.
The investigators found that the patients who received semaglutide were less likely to experience a composite outcome of all-cause mortality, myocardial infarction or stroke compared with those who received empagliflozin. Further, the patients who received semaglutide demonstrated greater weight loss and glycemic control.
The findings indicated that semaglutide could offer benefit over empagliflozin in this patient population.
Read more: Annals of Internal Medicine
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.